Prognostic role of microRNA-150 in various carcinomas: a meta-analysis

Figures & data

Figure 1 Flow diagram of study selection process.

Abbreviations: PFS, progression-free survival; OS, overall survival.

Table 1 Main features of the enrolled studies

References	Country	Tumor type	Study design	Number of studies	Age (median)	Dominant ethnicity	Sample	Survival	MicroRNA type
Yokobori et al^Citation9	Japan	Esophageal cancer	R	108	64.9	Asian	Tissue	OS	miR-23b
Dettmer et al^Citation14	Switzerland	Thyroid cancer	R	26	NR	Caucasian	Tissue	OS
Ma et al^Citation10	People’s Republic of China	Colorectal cancer	R	239	NR	Asian	Tissue	OS
Mraz et al^Citation6	USA	CLL	R	154	56.5	Caucasian	Tissue	OS
Ciruelos et al^Citation8	USA	Breast cancer	R	172	53.7	Caucasian	Tissue	OS/PFS	miR-30e, miR-30a, miR-21, miR-210, miR-93, miR-99b, and miR-572
Lee et al^Citation11	Korea	Pancreatic cancer	R	221	60.2	Asian	Tissue	OS	miR-99a, miR-194, miR-375, miR-342-3p, and miR-487b
Lee et al^Citation11	Korea	Pancreatic cancer	R	189	NR	Asian	Tissue	OS	miR-99a, miR-194, miR-375, miR-342-3p, and miR-487b
Stamatopoulos et al^Citation19	Belgium	CLL	R	273	63	Caucasian	Cell	OS
Stamatopoulos et al^Citation19	Belgium	CLL	R	252	69	Caucasian	Serum	OS
Bi et al^Citation7	People’s Republic of China	SCLC	R	40	50	Asian	Tissue	OS/PFS
Bi et al^Citation7	People’s Republic of China	SCLC	R	42	60.1	Asian	Tissue	OS/PFS
Fleming et al^Citation20	People’s Republic of China	Melanoma	R	201	61	Asian	Serum	OS	miR-30d, miR-15b, and miR-425
Fleming et al^Citation20	People’s Republic of China	Melanoma	R	82	59.9	Asian	Serum	OS	miR-30d, miR-15b, and miR-425

Note: Study design is described as P or R.

Abbreviations: CLL, chronic lymphocytic leukemia; NR, not reference; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective; SCLC, small-cell lung cancer.

Table 2 Difference in the overall survival and progression-free survival between high- and low-expression cases of microRNA-150 in the enrolled studies

References	Method	Cutoff value	Follow-up time (months)	miR-150 expression (number of cases)		OS		PFS
				High	Low	HR (95% CI)	P-value	HR (95% CI)	P-value
Yokobori et al^Citation9	qRT-PCR	Mean expression level	1–128	30	78	0.77 (0.31, 1.92)	0.5734	–	–
Dettmer et al^Citation14	qRT-PCR	Fold change =0.2	5.1–203.6	11	15	1.57 (0.30, 8.14)	0.5932	–	–
Ma et al^Citation10	qRT-PCR	The median value	NR	NR	NR	0.52 (0.31, 0.85)	0.0132	–	–
Mraz et al^Citation6	qRT-PCR	The median value	NR	NR	NR	0.36 (0.17, 0.77)	0.0076	–	–
Ciruelos et al^Citation8	qRT-PCR	NR	NR	NR	NR	4.51 (2.36, 8.61)	0.0000	3.75 (2.27, 6.19)	0.0000
Lee et al^Citation11	qRT-PCR	The median value	NR	111	110	1.69 (1.25, 2.27)	0.0007	–	–
Lee et al^Citation11	qRT-PCR	The median value	NR	93	96	1.74 (1.26, 2.41)	0.0008	–	–
Stamatopoulos et al^Citation19	qRT-PCR	The median value	7–380	180	93	0.53 (0.31, 0.93)	0.0203	–	–
Stamatopoulos et al^Citation19	qRT-PCR	The median value	7–380	133	119	2.06 (1.02, 4.15)	0.0439	–	–
Bi et al^Citation7	qRT-PCR	NR	4.4–104.2	20	20	3.05 (0.57, 16.39)	0.1926	1.6 (0.52, 4.97)	0.4124
Bi et al^Citation7	qRT-PCR	NR	9–81	21	21	2.12 (0.54, 8.22)	0.2816	2.02 (0.56, 7.30)	0.2828
Fleming et al^Citation20	qRT-PCR	Risk score cutoff: 0.2	17.5–128.9	106	95	2.21 (0.68, 7.19)	0.1873	–	–
Fleming et al^Citation20	qRT-PCR	Risk score cutoff: 0.2	0.8–95.0	41	41	2.34 (0.43, 12.78)	0.3253	–	–

Note: HR, high vs low.

Abbreviations: CI, confidence interval; HR, hazard ratio; miR-150, microRNA-150; NR, no reference; OS, overall survival; PFS, progression-free survival; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.

Figure 2 Forest plots of merged analyses of OS in association with microRNA-150 expression.

Notes: Squares and horizontal lines represent study-specific HRs and 95% CIs, respectively. The areas of the squares correspond to weights, and the diamonds represent the overall HRs and 95% CIs.
Abbreviations: CIs, confidence intervals; df, degrees of freedom; HRs, hazard ratios; OS, overall survival; SE, standard error; IV, inverse variance.

Figure 3 Forest plots of merged analyses of OS in different subgroups in association with microRNA-150 expression.

Notes: (A) Forest plots for the subgroup analysis of OS in different ethnicity. Squares and horizontal lines represent study-specific HRs and 95% CIs, respectively. The areas of the squares correspond to weights, and the diamonds represent the overall HRs and 95% CIs. (B) Forest plots for the subgroup analysis of OS in different diseases systems. (C) Forest plots for the subgroup analysis of OS in different detected samples.
Abbreviations: CIs, confidence intervals; df, degrees of freedom; HRs, hazard ratios; OS, overall survival; SE, standard error; IV, inverse variance.

Table 3 Pooled HRs, 95% CIs, and P-values for OS stratified by ethnicity, disease system, and detected sample for overall and subgroup analyses

Subgroup	Number of studies	OS
		pHR (95% CI)	P-values
Total	9
Ethnic subtotal
Caucasian	4	1.21 (0.44, 3.34)	0.72
Asian	5	1.36 (0.89, 2.09)	0.16
Disease system subtotal
Blood	2	0.73 (0.28, 1.94)	0.53
Digestive tract	2	0.57 (0.37, 0.90)	0.02
Detected sample subtotal
Tissue	6	1.27 (0.81, 2.01)	0.3
Serum	3	1.30 (0.45, 3.72)	0.63

Abbreviations: CIs, confidence intervals; HRs, hazard ratios; OS, overall survival; pHR, pooled hazard ratio.

Figure 4 Forest plots of merged analyses of PFS in association with microRNA-150 expression.

Notes: Squares and horizontal lines represent study-specific HRs and 95% CIs, respectively. The areas of the squares correspond to weights, and the diamonds represent the overall HRs and 95% CIs.
Abbreviations: CIs, confidence intervals; df, degrees of freedom; HRs, hazard ratios; PFS, progression-free survival; SE, standard error; IV, inverse variance.

Figure 5 Begg’s funnel plots of the publication bias for overall merged analysis of OS.

Note: Each point represents a separate study.
Abbreviations: HR, hazard ratio; OS, overall survival; SE, standard error.

YokoboriTSuzukiSTanakaNMiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1Cancer Sci20131041485423013135

 PubMed Web of Science ®Google Scholar

DettmerMSPerrenAMochHKomminothPNikiforovYENikiforovaMNMicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insightsJ Mol Endocrinol201452218118924443580

 PubMed Web of Science ®Google Scholar

MaYZhangPWangFmiR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancerGut201261101447145322052060

 PubMed Web of Science ®Google Scholar

MrazMChenLRassentiLZmiR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1Blood20141241849524787006

 PubMed Web of Science ®Google Scholar

CiruelosEDe VelascoGAGamezAClinical significance of microRNA expression as aprognostic factor in early N+ breast cancer (BC)Cancer Res201223196

 Google Scholar

LeeKHLeeJKChoiDWPostoperative prognosis prediction of pancreatic cancer with seven microRNAsPancreas201544576476825906450

 PubMed Web of Science ®Google Scholar

StamatopoulosBVan DammeMCrompotEOpposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemiaMol Med20152112313325584781

 PubMed Web of Science ®Google Scholar

BiNCaoJSongYA microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapyPLoS One201493e9138824637927

 PubMed Web of Science ®Google Scholar

FlemingNHZhongJda SilvaSerum-based miRNAs in the prediction and detection of recurrence in melanoma patientsCancer20151211515925155861

 PubMed Web of Science ®Google Scholar